Cluster Headache Market

DelveInsight’s ‘Cluster Headache Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of and historical and forecasted epidemiology as well as the market trends of Cluster Headache in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Cluster Headache market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted Cluster Headache symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Cluster Headache symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

 

Study Period: 2018–2030

Cluster Headache Disease Understanding and Treatment Algorithm

Cluster Headache Overview

According to the National Organization of Rare Diseases (NORD), Cluster headaches (CHs) are an uncommon, severe form of primary neurovascular headaches. CH is the most painful form of headaches, with the pain occurring on one side of the head and behind or above the eye or at the temple most commonly.

CH is subcategorized into episodic and chronic forms based on certain factors like duration, frequency, periodicity, etc. In episodic cluster headache (ECH), at least two cluster periods lasting 7 days to 1 year, separated by pain-free periods lasting 1 month or more, are seen. In chronic cluster headache (CCH), attacks occur for more than 1 year without remission or with remission lasting less than 1 month.

Patients with CH have typical trigeminal-autonomic symptoms, such as ptosis (drooping of the upper eyelid), sweating, and miosis (constriction of pupils). In addition to trigeminal-autonomic symptoms, a large proportion of patients with CH have migraine-like features such as photophobia (sensitivity to light) or osmophobia (hypersensitivity to odors); thus, many patients are not correctly diagnosed and are misdiagnosed with a migraine disorder instead.

 

Cluster Headache Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnoses available in the Cluster Headache market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.


The DelveInsight Cluster Headache market report gives a thorough understanding of Cluster Headache symptoms by including disease definition, symptoms, causes, physiology, and diagnosis. It also provides Cluster Headache symptoms of treatment algorithms and treatment guidelines for Cluster Headache symptoms in the US, Europe, and Japan.


The recommended technique for diagnosis is MRI with or without contrast enhancement and fine slices through the pituitary gland region (as pituitary tumors can manifest with secondary headaches with a cluster phenotype). If a pituitary gland lesion is suspected or confirmed by imaging, laboratory testing for levels of pituitary hormones is indicated.


The treatment of cluster headache can be divided into three treatment phases: a fast-acting abortive treatment, preventive drugs, and transitional treatment to bridge the period between patients starting preventive drug dosages and the drugs asserting an effect. The main goal in cluster headache treatment should always be to prevent all attacks.

Cluster Headache Epidemiology

The Cluster Headache symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends and assumptions undertaken.


Key Findings

The total prevalent cases of Cluster Headache are increasing by 7MM during the study period, i.e., 2018–2030.

The disease epidemiology covered in the report provides historical as well as forecasted Cluster Headache symptoms epidemiology segmented as the prevalence of Cluster Headache, diagnosed cases of Cluster Headache, type-specific cases of Cluster Headache, gender-specific cases of Cluster Headache, and age-specific cases of Cluster Headache. The report includes the prevalent scenario of Cluster Headache symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.


Country-wise Cluster Headache Epidemiology

The epidemiology segment also provides the Cluster Headache epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total prevalent cases of Cluster Headache associated in 7MM countries was 877,859 in 2020.

Cluster Headache Drug Chapters

The Cluster Headache report’s drug chapter segment encloses the detailed analysis of Cluster Headache’s early-stage (Phase- I, II, and III) pipeline drugs. It also helps understand the Cluster Headache clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.


Cluster Headache Emerging Drug


VYEPTI (Eptinezumab): Lundbeck Seattle BioPharmaceutical

Eptinezumab (ALD-403), sold under the brand name VYEPTI, is a medication for the preventive treatment of migraine in adults. It is a monoclonal antibody that targets calcitonin gene-related peptides (CGRP) alpha and beta. It is administered by intravenous infusion every 3 months.


Civamide (Zucapsaicin): Winston Laboratories

Zucapsaicin (Civanex) is a medication used to treat osteoarthritis of the knee and other neuropathic pain. It is applied three times daily for a maximum of three months. Zucapsaicin is a member of phenols and a member of methoxybenzenes. It is a modulator of transient-receptor potential-cation channel subfamily V member 1 (TRPV-1), also known as the vanilloid or capsaicin receptor 1, which reduces pain and improves articular functions. It is the cis-isomer of capsaicin.

Products detail in the report…

Cluster Headache Market Outlook

The Cluster Headache market outlook helps build a detailed comprehension of the historical, current, and forecasted Cluster Headache market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Cluster Headache market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Cluster Headache market in 7MM is expected to grow in the study period 2018–2030.


As per DelveInsight’s analysis, the number of patients suffering from the episodic form is much higher than those suffering from the chronic form. In the US, in 2018, there were 157,040 cases of the episodic form of CH and 39,260 cases of the chronic form of CH. These are projected to increase to 170,448 and 42,612 cases for episodic and chronic form, respectively. The treatment for cluster headache can be divided into three treatment phases: a fast-acting abortive treatment, preventive drugs, and transitional treatment to bridge the period between patients starting preventive drug dosages and the drugs asserting an effect. The acute treatment includes Triptans, High-flow oxygen, Somatostatin, and Somatostatin Analogues, among others. Prophylactic treatment drugs of the first choice are verapamil, lithium, and topiramate.


Key Findings

This section includes a glimpse of the Cluster Headache market in the 7MM.

The market size of Cluster Headache in the seven major markets was USD 741.8 million in 2020.


The United States Market Outlook

This section provides the total Cluster Headache market size and market size by therapies in the United States.

The United States accounts for the largest market size of Cluster Headache in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.


EU-5 Countries: Market Outlook

The total Cluster Headache market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.


Japan Market Outlook

The total Cluster Headache market Size and market Size by therapies in Japan are also mentioned.

Cluster Headache Drugs Uptake

This section focuses on the uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers the Cluster Headache market uptake by drugs, patient uptake by therapies, and sales of each drug. 

This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Cluster Headache Pipeline Development Activities

The report provides insights into the therapeutic candidate in Phase I, II, and III stages. It also analyses Cluster Headache’s key players involved in developing targeted therapeutics.

Major players include Lundbeck Seattle BioPharmaceuticals and Winston Laboratories.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Cluster Headache emerging therapies.

Reimbursement Scenario in Cluster Headache

Proactively approaching reimbursement can positively impact both during the early stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

 

A prospective study by Negro et al. (2020) aimed to quantify the total direct and indirect cost of ECH and CCH over a cluster period, both for the patient and the National Health System (NHS), using data from subjects who consecutively attended an Italian tertiary headache center between January 1, 2018, and December 31, 2018. A total of 108 patients (89 ECH, 19 CCH) were included. The mean attack frequency was 2.3 ± 1.4 per day. The mean total cost of a CH bout was EUR 4398 per patient, and the total cost of CCH was 5.4 times higher than ECH (EUR 13,350 vs. EUR 2487, p < 0.001). Direct costs represented 72.1% of total cost and were covered for the 94.8% by the NHS. The costs for any item of expense were higher for CCH than for ECH (p < 0.001). Mean indirect costs for a CH bout were EUR 1,226 per patient and higher for CCH than ECH (EUR 3,538 vs. EUR 732), but the difference was not significant. Days with reduced productive capacity impacted 64.6% of the total indirect costs. The analysis of the impact of CH on work showed that 27%% of patients felt that CH had limited their career, 40% had changed their work pattern, 20% had changed their place of employment, and 10% had lost a job due to the disease. The results provide a valuable estimate of the direct and indirect costs of ECH and CCH in the specific setting of a tertiary headache center and confirm the high economic impact of CH on both the NHS and patients.

KOL Views

To keep up with current market trends, we take KOLs’ and SMEs’ opinions working in the Cluster Headache domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or Cluster Headache market trends. This will support the clients in potential upcoming novel treatment by identifying the market's overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Cluster Headache Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Cluster Headache, explaining its causes, signs and symptoms, physiology, and currently available therapies.
  • Comprehensive insight has been provided into the Cluster Headache epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Cluster Headache is provided, along with the assessment of new therapies, which will impact the current treatment landscape.
  • A detailed review of the Cluster Headache market, historical and forecasted, is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Cluster Headache market.

Report Highlights

  • In the coming years, the Cluster Headache market is set to change due to the rising awareness of the disease and the favorable environment for new anti-infective modalities, expanding the market’s size to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Cluster Headache R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Cluster Headache. The launch of emerging therapies will significantly impact the Cluster Headache market.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase I, II, and III), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, and launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Cluster Headache Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Cluster Headache Pipeline Analysis
  • Cluster Headache Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Cluster Headache Report Key Strengths

  • 10-years Forecast
  • 7MM Coverage
  • Cluster Headache Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Cluster Headache Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Cluster Headache market share (%) distribution in 2018, and how would it look in 2030?
  • What would be the Cluster Headache total market Size as well as market Size by therapies across the 7MM during the study period (2018–2030)?
  • What are the market's key findings across 7MM, and which country will have the largest Cluster Headache market Size during the study period (2018–2030)?
  • At what CAGR, the Cluster Headache market is expected to grow by 7MM during the study period (2018–2030)?
  • What would be the Cluster Headache market outlook across the 7MM during the study period (2018–2030)?
  • What would be the Cluster Headache market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What are the disease risk, burdens, and unmet needs of Cluster Headache?
  • What is the historical Cluster Headache patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Cluster Headache in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about Cluster Headache?
  • Out of all 7MM countries, which country would have the largest prevalent Cluster Headache population during the study period (2018–2030)?
  • At what CAGR is the population expected to grow by 7MM during the study period (2018–2030)?


Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Cluster Headache along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Cluster Headache in the USA, Europe, and Japan?
  • What are the Cluster Headache marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, and safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Cluster Headache?
  • How many therapies are developed by each company for the treatment of Cluster Headache?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Cluster Headache?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to Cluster Headache therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Cluster Headache and their status?
  • What are the key designations that have been granted for the emerging therapies for Cluster Headache?
  • What are the global historical and forecasted markets of Cluster Headache?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Cluster Headache market.
  • To understand the future market competition in the Cluster Headache market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Cluster Headache in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Cluster Headache market.
  • To understand the future market competition in the Cluster Headache market.

1 Key Insights

2 Report Introduction

3 Cluster Headache Market Overview at a Glance

3.1 Market Share (%) Distribution of Cluster Headache in 2018

3.2 Market Share (%) Distribution of Cluster Headache in 2030

4 Executive Summary of Cluster Headache

5 Disease Background and Overview

5.1 Introduction

5.2 Classification of Cluster Headache

5.3 Clinical Characteristics

5.4 Comorbidities associated with Cluster Headache

5.5 Cluster Headache versus Migraine

5.6 Risk Factors associated with Cluster Headache

5.7 Pathophysiology

5.1.1 Trigeminovascular System

5.1.2 Parasympathetic Activation

5.1.3 Hypothalamus Activation

5.8 Diagnosis

5.1.4 Differential Diagnosis

5.9 Treatment

6 Epidemiology and Patient Population

6.1 Key Findings

6.2 7MM Total Diagnosed Incident Population of Cluster Headache

6.3 Epidemiology of Cluster Headache

6.4 The United States

6.4.1 Prevalence of Cluster Headache in the United States

6.4.2 Diagnosed cases of Cluster Headache in the United States

6.4.3 Type-specific cases of Cluster Headache in the United States

6.4.4 Gender-specific cases of Cluster Headache in the United States

6.4.5 Age-specific cases of Cluster Headache in the United States

6.5 EU5

6.5.1 Germany

6.5.1.1 Prevalence of Cluster Headache in Germany

6.5.1.2 Diagnosed cases of Cluster Headache in Germany

6.5.1.3 Type-specific cases of Cluster Headache in Germany

6.5.1.4 Gender-specific cases of Cluster Headache in Germany

6.5.1.5 Age-specific cases of Cluster Headache in Germany

6.5.2 France

6.5.2.1 Prevalence of Cluster Headache in France

6.5.2.2 Diagnosed cases of Cluster Headache in France

6.5.2.3 Type-specific cases of Cluster Headache in France

6.5.2.4 Gender-specific cases of Cluster Headache in France

6.5.2.5 Age-specific cases of Cluster Headache in France

6.5.3 Italy

6.5.3.1 Prevalence of Cluster Headache in Italy

6.5.3.2 Diagnosed cases of Cluster Headache in Italy

6.5.3.3 Type-specific cases of Cluster Headache in Italy

6.5.3.4 Gender-specific cases of Cluster Headache in Italy

6.5.3.5 Age-specific cases of Cluster Headache in Italy

6.5.4 Spain

6.5.4.1 Prevalence of Cluster Headache in Spain

6.5.4.2 Diagnosed cases of Cluster Headache in Spain

6.5.4.3 Type-specific cases of Cluster Headache in Spain

6.5.4.4 Gender-specific cases of Cluster Headache in Spain

6.5.4.5 Age-specific cases of Cluster Headache in Spain

6.5.5 United Kingdom

6.5.5.1 Prevalence of Cluster Headache in the United Kingdom

6.5.5.2 Diagnosed cases of Cluster Headache in the United Kingdom

6.5.5.3 Type-specific cases of Cluster Headache in the United Kingdom

6.5.5.4 Gender-specific cases of Cluster Headache in the United Kingdom

6.5.5.5 Age-specific cases of Cluster Headache in the United Kingdom

6.6 Japan

6.6.1 Prevalence of Cluster Headache in Japan

6.6.2 Diagnosed cases of Cluster Headache in Japan

6.6.3 Type-specific cases of Cluster Headache in Japan

6.6.4 Gender-specific cases of Cluster Headache in Japan

6.6.5 Age-specific Cases of Cluster Headache in Japan

7 Organizations contributing towards Cluster Headache

8 Patient Journey

9 Case Reports

10 Marketed Products

10.1 EMGALITY (Galcanezumab-gnlm): Eli Lilly and Company

10.1.1 Product Description

10.1.2 Mechanism of action

10.1.3 Regulatory Milestones

10.1.4 Safety and Efficacy of EMGALITY

10.1.5 Product Profile

11 Emerging Therapies

11.1 Key Cross Competition

11.2 VYEPTI (Eptinezumab): Lundbeck Seattle BioPharmaceutical

11.2.1 Drug Description

11.2.2 Regulatory Milestones

11.2.3 Clinical Development

11.2.4 Clinical Trials Information

11.2.5 Safety and Efficacy

11.2.6 Product Profile

11.3 Civamide (Zucapsaicin): Winston Laboratories

11.3.1 Drug Description

11.3.2 Regulatory Milestones

11.3.3 Clinical Development

11.3.4 Clinical Trials Information

11.3.5 Safety and Efficacy

11.3.6 Product Profile

12 Other Drugs under Development

12.1 Zolmitriptan transdermal (C213): Zosano Pharma

12.1.1 Drug Description

12.1.2 Clinical Development

12.1.3 Clinical Trials Information

12.1.4 Product Profile

13 Cluster Headache: Seven Major Market Analysis

13.1 Key Findings

13.2 Market Size of Cluster Headache in 7MM

13.3 Market Outlook

13.4 United States Market Size

13.1.1 Total Market Size of Cluster Headache in the United States

13.1.2 Market Size of Cluster Headache by Therapies in the United States

13.5 EU-5 Market Size

13.2.1 Germany

13.2.1.1 Total Market Size of Cluster Headache in Germany

13.2.1.2 Market Size of Cluster Headache by Therapies in Germany

13.2.2 France

13.2.2.1 Total Market Size of Cluster Headache in France

13.2.2.2 Market Size of Cluster Headache by Therapies in France

13.2.3 Italy

13.2.3.1 Total Market Size of Cluster Headache in Italy

13.2.3.2 Market Size of Cluster Headache by Therapies in Italy

13.2.4 Spain

13.2.4.1 Total Market Size of Cluster Headache in Spain

13.2.4.2 Market Size of Cluster Headache by Therapies in Spain

13.2.5 United Kingdom

13.2.5.1 Total Market Size of Cluster Headache in the United Kingdom

13.2.5.2 Market Size of Cluster Headache by Therapies in the United Kingdom

13.6 Japan

13.3.1 Total Market size of Cluster Headache in Japan

13.3.2 Market Size of Cluster Headache by Therapies in Japan

14 KOL Views

15 Market Drivers

16 Market Barriers

17 SWOT Analysis

18 Unmet Needs

19 Market Access

20 Appendix

20.1 Bibliography

20.2 Report Methodology

21 DelveInsight Capabilities

22 Disclaimer

23 About DelveInsight

Table 1: Summary of Cluster Headache, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Difference between Cluster Headache and Migraine

Table 3: Characteristics of cluster headache and other headache types that can have overlapping features

Table 4- Recommendations AHS made for the treatment of CH made according to AAN grades for classification

Table 5- Efficacy, Adverse Events, Level of Evidence and Recommendations for the Acute Therapy of Cluster Headache

Table 6- Efficacy, Adverse Events, Level of Evidence and Recommendations for the Therapy of Cluster Headache

Table 7: Diagnosed Incident Population of Cluster Headache in 7MM (2018–2030)

Table 8: Prevalence of Cluster Headache in the United States (2018–2030)

Table 9: Diagnosed cases of Cluster Headache in the United States (2018–2030)

Table 10: Type-specific cases of Cluster Headache in the United States (2018–2030)

Table 11: Gender-specific cases of Cluster Headache in the United States (2018–2030)

Table 12: Age-specific cases of Cluster Headache in the United States (2018–2030)

Table 13: Prevalence of Cluster Headache in Germany (2018–2030)

Table 14: Diagnosed cases of Cluster Headache in Germany (2018–2030)

Table 15: Type-specific cases of Cluster Headache in Germany (2018–2030)

Table 16: Gender-specific cases of Cluster Headache in Germany (2018–2030)

Table 17: Age-specific Cases of Cluster Headache in Germany (2018–2030)

Table 18: Prevalence of Cluster Headache in France (2018–2030)

Table 19: Diagnosed of Cluster Headache in France (2018–2030)

Table 20: Type-specific cases of Cluster Headache in France (2018–2030)

Table 21: Gender-specific cases of Cluster Headache in France (2018–2030)

Table 22: Age-specific Cases of Cluster Headache in France (2018–2030)

Table 23: Prevalence of Cluster Headache in Italy (2018–2030)

Table 24: Diagnosed of Cluster Headache in Italy (2018–2030)

Table 25: Type-specific cases of Cluster Headache in Italy (2018–2030)

Table 26: Gender-specific cases of Cluster Headache in Italy (2018–2030)

Table 27: Age-specific Cases of Cluster Headache in Italy (2018–2030)

Table 28: Prevalence of Cluster Headache in Spain (2018–2030)

Table 29: Diagnosed of Cluster Headache in Spain (2018–2030)

Table 30: Type-specific cases of Cluster Headache in Spain (2018–2030)

Table 31: Gender-specific cases of Cluster Headache in Spain (2018–2030)

Table 32: Age-specific Cases of Cluster Headache in Spain (2018–2030)

Table 33: Prevalence of Cluster Headache in the United Kingdom (2018–2030)

Table 34: Diagnosed of Cluster Headache in the UK (2018–2030)

Table 35: Type-specific cases of Cluster Headache in the UK (2018–2030)

Table 36: Gender-specific cases of Cluster Headache in the United Kingdom (2018–2030)

Table 37: Age-specific Cases of Cluster Headache in the United Kingdom (2018–2030)

Table 38: Prevalence of Cluster Headache in Japan (2018–2030)

Table 39: Diagnosed cases of Cluster Headache in Japan (2018–2030)

Table 40: Type-specific cases of Cluster Headache in Japan (2018–2030)

Table 41: Gender-specific cases of Cluster Headache in Japan (2018–2030)

Table 42: Age-specific Cases of Cluster Headache in Japan (2018–2030)

Table 43: Organization contributing to fight against synovial sarcoma

Table 44: Zolmitriptan transdermal, Clinical Trial Description, 2021

Table 45: Eptinezumab, Clinical Trial Description, 2021

Table 46: Civamide, Clinical Trial Description, 2021

Table 47: Seven Major Market Size of Cluster Headache in USD Million (2018–2030)

Table 48: United States Market Size of Cluster Headache in USD Million (2018–2030)

Table 49: United States Market Size of Cluster Headache by Therapies in USD Million (2018–2030)

Table 50: Germany Market Size of Cluster Headache in USD Million (2018–2030)

Table 51: Germany Market Size of Cluster Headache by Therapies in USD Million (2018–2030)

Table 52: France Market Size of Cluster Headache in USD Million (2018–2030)

Table 53: France Market Size of Cluster Headache by Therapies in USD Million (2018–2030)

Table 54: Italy Market Size of Cluster Headache in USD Million (2018–2030)

Table 55: Italy Market Size of Cluster Headache by Therapies in USD Million (2018–2030)

Table 56: Spain Market Size of Cluster Headache in USD Million (2018–2030)

Table 57: Spain Market Size of Cluster Headache by Therapies in USD Million (2018–2030)

Table 58: United Kingdom Market Size of Cluster Headache in USD Million (2018–2030)

Table 59: United Kingdom Market Size of Cluster Headache by Therapies in USD Million (2018–2030)

Table 60: Japan Market Size of Cluster Headache in USD Million (2018–2030)

Table 61: Japan Market Size of Cluster Headache by Therapies in USD Million (2018–2030)

Figure 1: Hypothetical pathophysiological model of cluster headache

Figure 2: Anatomical and neurotransmitter components of cluster headache pathophysiology

Figure 3: Cluster headache diagnostic criteria (adapted from International Classification of Headache Disorders, Third Edition)

Figure 4: Diagnostic Algorithm for Cluster Headache

Figure 5: Diagnosed Incident Population of Cluster Headache in 7MM (2018–2030)

Figure 6: Prevalence of Cluster Headache in the United States (2018–2030)

Figure 7: Diagnosed cases of Cluster Headache in the United States (2018–2030)

Figure 8: Type-specific cases of Cluster Headache in the United States (2018–2030)

Figure 9: Gender-specific cases of Cluster Headache in the United States (2018–2030)

Figure 10: Age-specific cases of Cluster Headache in the United States (2018–2030)

Figure 11: Prevalence of Cluster Headache in Germany (2018–2030)

Figure 12: Diagnosed cases of Cluster Headache in Germany (2018–2030)

Figure 13: Type-specific cases of Cluster Headache in Germany (2018–2030)

Figure 14: Gender-specific cases of Cluster Headache in Germany (2018–2030)

Figure 15: Age-specific Cases of Cluster Headache in Germany (2018–2030)

Figure 16: Prevalence of Cluster Headache in France (2018–2030)

Figure 17: Diagnosed cases of Cluster Headache in France (2018–2030)

Figure 18: Type-specific cases of Cluster Headache in France (2018–2030)

Figure 19: Gender-specific cases of Cluster Headache in France (2018–2030)

Figure 20: Age-specific Cases of Cluster Headache in France (2018–2030)

Figure 21: Prevalence of Cluster Headache in Italy (2018–2030)

Figure 22: Diagnosed cases of Cluster Headache in Italy (2018–2030)

Figure 23: Type-specific cases of Cluster Headache in Italy (2018–2030)

Figure 24: Gender-specific cases of Cluster Headache in Italy (2018–2030)

Figure 25: Age-specific Cases of Cluster Headache in Italy (2018–2030)

Figure 26: Prevalence of Cluster Headache in Spain (2018–2030)

Figure 27: Diagnosed cases of Cluster Headache in Spain (2018–2030)

Figure 28: Type-specific cases of Cluster Headache in Spain (2018–2030)

Figure 29: Gender-specific cases of Cluster Headache in Spain (2018–2030)

Figure 30: Age-specific Cases of Cluster Headache in Spain (2018–2030)

Figure 31: Prevalence of Cluster Headache in the United Kingdom (2018–2030)

Figure 32: Diagnosed cases of Cluster Headache in the UK (2018–2030)

Figure 33: Type-specific cases of Cluster Headache in the UK (2018–2030)

Figure 34: Gender-specific cases of Cluster Headache in the United Kingdom (2018–2030)

Figure 35: Age-specific Cases of Cluster Headache in the United Kingdom (2018–2030)

Figure 36: Prevalence of Cluster Headache in Japan (2018–2030)

Figure 37: Diagnosed cases of Cluster Headache in Japan (2018–2030)

Figure 38: Type-specific cases of Cluster Headache in Japan (2018–2030)

Figure 39: Gender-specific cases of Cluster Headache in Japan (2018–2030)

Figure 40: Age-specific Cases of Cluster Headache in Japan (2018–2030)

Figure 41: Seven Major Market Size of Cluster Headache in USD Million (2018–2030)

Figure 42: Market Size of Cluster Headache in the United States, USD Million (2018–2030)

Figure 43: The United States Market Size of Cluster Headache by Therapies in USD Million

Figure 44: Market Size of Cluster Headache in Germany, USD Million (2018–2030)

Figure 45: Germany Market Size of Cluster Headache by Therapies in USD Million

Figure 46: Market Size of Cluster Headache in France, USD Million (2018–2030)

Figure 47: France Market Size of Cluster Headache by Therapies in USD Million

Figure 48: Market Size of Cluster Headache in Italy, USD Million (2018–2030)

Figure 49: Italy Market Size of Cluster Headache by Therapies in USD Million

Figure 50: Market Size of Cluster Headache in Spain, USD Million (2018–2030)

Figure 51: Spain Market Size of Cluster Headache by Therapies in USD Million

Figure 52: Market Size of Cluster Headache in the United Kingdom, USD Million (2018–2030)

Figure 53: The United Kingdom Market Size of Cluster Headache by Therapies in USD Million

Figure 54: Market Size of Cluster Headache in Japan, USD Million (2018–2030)

Figure 55: Japan Market Size of Cluster Headache by Therapies in USD Million

Eli Lilly and Company

Lundbeck Seattle BioPharmaceutical

Winston Laboratories

Zosano Pharma

  • Tags:
  • Cluster Headache Market

Forward to Friend

Need A Quote